202857-88-3

Basic information

• Product Name: 2-(benzyloxy)-1-broMo-4-fluorobenzene
• Synonyms: 2-(benzyloxy)-1-broMo-4-fluorobenzene;Benzene, 1-broMo-4-fluoro-2-(phenylMethoxy)-
• CAS NO: 202857-88-3
• Molecular Formula: C₁₃H₁₀BrFO
• Molecular Weight: 281.1203032
• Mol File: 202857-88-3.mol

Chemical Properties

• Boiling Point: 322.8±27.0 °C(Predicted)
• Appearance: /
• Density: 1.445±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(benzyloxy)-1-broMo-4-fluorobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(benzyloxy)-1-broMo-4-fluorobenzene(202857-88-3)
• EPA Substance Registry System: 2-(benzyloxy)-1-broMo-4-fluorobenzene(202857-88-3)

Safety Data

• Hazardous Substances Data: 202857-88-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(Benzyloxy)-1-bromo-4-fluorobenzene is used as a reactant in the synthesis of furan-2-ylmethylene thiazolidinedione derivatives. These derivatives are potent and selective inhibitors of phosphoinositide 3-kinase γ (PI3Kγ), an enzyme that plays a crucial role in various cellular processes, including cell growth, survival, and metabolism. Inhibition of PI3Kγ has been shown to have therapeutic potential in the treatment of various diseases, such as inflammatory and autoimmune disorders, as well as cancer.
In the synthesis process, 2-(benzyloxy)-1-bromo-4-fluorobenzene serves as a key building block, providing the necessary structural features for the formation of the final product. Its reactivity and functional group compatibility make it an ideal candidate for the preparation of biologically active compounds with potential applications in medicine.

Upstream product

• 348-57-2 2,4-difluorobromobenzene 
• 100-51-6 benzyl alcohol 
• 100-39-0 benzyl bromide 
• 147460-41-1 2-bromo-5-fluorophenol 

Downstream Products

• 202857-89-4 2-(benzyloxy)-4-fluorobenzaldehyde 
• 150356-67-5 1-bromo-4-methoxy-2-(phenylmethoxy)benzene 
• 861928-80-5 [2-(2-benzyloxy-4-fluoro-phenyl)-6-methoxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone 
• 1469327-04-5 2-(benzyloxy)-3-bromo-6-fluorobenzaldehyde 
• 1469327-06-7 tert-butyl 4-[4-(benzyloxy)-5-methyl-1H-indazole-1-yl]piperidine-1-carboxylate 
• 1469327-05-6 tert-butyl 4-[4-(benzyloxy)-5-bromo-1H-indazole-1-yl]piperidine-1-carboxylate 
• 850363-66-5 4-(benzyloxy)-5-bromo-1H-indazole 
• 900515-16-4 (5Z)-5-[[5-(4-fluoro-2-hydroxyphenyl)furan-2-yl]methylidene]-1,3-thiazolidine-2,4-dione 
• 900515-33-5 5-(4-fluoro-2-hydroxyphenyl)furan-2-carbaldehyde 
• 900515-32-4 5-(2-benzyloxy-4-fluorophenyl)furan-2-carbaldehyde 

Relevant articles and documents

PHARMACEUTICALS CONTAINING NOVEL 1-POSITION SUBSTITUTED INDAZOLE DERIVATIVE

PROBLEM TO BE SOLVED: To provide pharmaceuticals containing a compound having strong effect of modulating α7 nicotinic acetylcholine receptor (α7nAChR) and useful as treatment agent for diseases related to cholinergic in central nervous system (CNS) and/o

NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE

A medicament for treating diseases associated with cholinergic properties in the central nervous system (CNS) and/or peripheral nervous system (PNS), diseases associated with smooth muscle contraction, endocrine disorders, neurodegenerative disorders and

Regioselective SNAr reactions of substituted difluorobenzene derivatives: practical synthesis of fluoroaryl ethers and substituted resorcinols

In this Letter, we describe a practical and highly selective method for the preparation of fluoroaryl ethers and differentially substituted resorcinol derivatives. This synthetic strategy relies on a selective SNAr of substituted difluorobenzen

Regioselectivity of fluorine substitution by alkoxides on unsymmetrical difluoroarenes

An efficient approach to unsymmetrical halogenated resorcinol diethers has been developed. This synthesis consists of two subsequent nucleophilic aromatic substitutions (SNAr) of unsymmetrical difluoroarenes by alkoxides. The novelty of this ap

HIV INTEGRASE INHIBITORS

The present invention features compounds that are HIV integrase inhibitors useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES

A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is -O-, -CH2-, or -NH-; n is an integer selected between 0 and 1; R6 and R7 each independently is hydrogen or C1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q1 to Q5; Ar1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase γ

Class I phosphoinositide 3-kinases (PI3Ks), in particular PI3Kγ, have become attractive drug targets for inflammatory and autoimmune diseases. Here, we disclose a novel series of furan-2-ylmethylene thiazolidinediones as selective, ATP-competitive PI3Kγ i

Substituted biphenyls

Substituted biphenyls having glucagon receptor antagonistic activity. Claimed compounds have the formula wherein R1aand R1bindependently represent (C1-C6) alkyl; R2represents (C1-C10) alkyl or substituted (C1-C10) alkyl wherein the substituents are independently from 1 to 3 of —SR7; R7represents phenyl, or substituted phenyl wherein the substituents are independently 1-5 of halogen, trifluoromethyl, (C1-C6) alkyl, (C1-C6) alkoxy, nitro, cyano, or hydroxyl; R3represents substituted (C1-C6) alkyl wherein the substituents are 1-2 hydroxyl groups; G represents a substituent selected from the group consisting of halogen, (C1-C6) alkyl, and OR4wherein R4is H or (C1-C6) alkyl; and y is 0 or an integer of 1-3. Pharmaceutical compositions containing such compounds and methods of treatment of glucagon-mediated conditions by administering such compounds are also claimed.